{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:35:03Z","timestamp":1786739703895,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"\n Objectives:<\/jats:title>\n This study was conducted to investigate the potential role of clinical pharmacists in monitoring and developing a reporting system of radiation-related adverse events (RRAEs) in cancer patients and provided suggestive measures to prevent RRAEs to achieve a better therapeutic outcome for improving patient health-related quality of life.<\/jats:p>\n <\/jats:sec>\n \n Methodology:<\/jats:title>\n This study was a prospective observational study conducted for a period of 2 years at a private academic oncology teaching care hospital. Patients on radiation therapy or chemoradiation therapy were enrolled and followed by clinical pharmacists on daily basis to identify adverse event(s) if any. Upon identification, adverse events were discussed with concerned radiation oncologists for authentication and graded as defined by the radiation therapy oncology group. Enrolled patients were also followed to ensure if they were provided adequate supportive care for RRAEs.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n A total of 715 patients were followed during the study period. A total of 422 RRAEs were identified in patients who were on radiation therapy or chemoradiation therapy. The most common reported events were fatigue (\n n<\/jats:italic>\n = 64, 15.16%), followed by mucositis (\n n<\/jats:italic>\n = 55, 13.03%), diarrhea (\n n<\/jats:italic>\n = 37, 8.76%), vomiting (\n n<\/jats:italic>\n = 31, 7.34%), gastritis (\n n<\/jats:italic>\n = 29, 6.87%), and dryness of the mouth (\n n<\/jats:italic>\n = 22, 5.21%). Among the study patients who developed RRAEs, majority (\n n<\/jats:italic>\n = 253, 60%) of them received a combination of chemotherapy and radiation therapy and 169 (40%) of 442 patients received radiotherapy alone. Cisplatin weekly monotherapy or cisplatin-based chemotherapy was commonly used pharmacological treatment in patients on chemoradiation therapy. Clinical pharmacists intervened to initiate adequate supportive care for nearly 20% (\n n<\/jats:italic>\n = 84) patients.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Clinical pharmacists may be contributing to monitoring and development of reporting systems for radiation-related toxicities\/RRAEs in cancer patients. Teamwork of clinical pharmacists with radiation oncologists can improve the safety reporting of radiation and can ensure required medical and supportive care to manage RRAEs.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/picr.picr_272_20","type":"journal-article","created":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T07:31:51Z","timestamp":1629531111000},"page":"205-210","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["An observational study to monitor and report radiation-related adverse events by a clinical pharmacist to achieve a better therapeutic outcome and suggest preventive measures in a tertiary care teaching hospital"],"prefix":"10.4103","volume":"13","author":[{"given":"Rajesh","family":"Hadia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trupal","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-7-20240829","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R3-7-20240829","doi-asserted-by":"crossref","first-page":"e663","DOI":"10.1016\/S1470-2045(18)30839-8","article-title":"Cancer trends and burden in India","volume":"19","author":"Chandramohan","year":"2018","journal-title":"Lancet Oncol"},{"key":"R5-7-20240829","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0305-7372(03)00117-8","article-title":"Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer","volume":"29","author":"Maduro","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"R6-7-20240829","first-page":"S071","article-title":"Reporting and monitoring of radiation related adverse events by clinical pharmacists in cancer patients: A pilot study","volume":"8","author":"Patel","year":"2017","journal-title":"J Basic Clin Phar"},{"key":"R8-7-20240829","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3747\/co.v17i4.522","article-title":"Evaluating the impact on quality of life of chemoradiation in gastric cancer","volume":"17","author":"Kassam","year":"2010","journal-title":"Curr Oncol"},{"key":"R10-7-20240829","doi-asserted-by":"crossref","first-page":"e7765","DOI":"10.1136\/bmj.e7765","article-title":"Advances in radiotherapy","volume":"345","author":"Ahmad","year":"2012","journal-title":"BMJ"},{"key":"R12-7-20240829","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijrobp.2005.04.025","article-title":"Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression","volume":"64","author":"van de Bunt","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R13-7-20240829","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0360-3016(01)01664-9","article-title":"Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation","volume":"51","author":"Portelance","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R15-7-20240829","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0167-8140(02)00404-8","article-title":"Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review","volume":"66","author":"Trotti","year":"2003","journal-title":"Radiother Oncol"}],"container-title":["Perspectives in Clinical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.PICR_272_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:31:37Z","timestamp":1786735897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.PICR_272_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/picr.picr_272_20","relation":{},"ISSN":["2229-3485"],"issn-type":[{"value":"2229-3485","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}